Exploring the Inflammatory Signature of the anti-cancer Smac-mimetic, Birinapant, and the contribution of this signature to Birinapant anti-Tumour activity
Exploring the Inflammatory Signature of the anti-cancer Smac-mimetic, Birinapant, and the contribution of this signature to Birinapant anti-Tumour activity
批准号:
nhmrc : GNT1101244
负责人:
Dr Conor Kearney
金额:
$19.23万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2016
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2016-01-01 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Programmed cell death (PCD) is an essential process for the removal of cancer cells. Defects in PCD are now known to be a causal factor in cancer initiation and chemotherapeutic resistance. Proteins called IAPs protect cancer cells from PCD, however, inhibitors of IAPs have been developed to kill cancer cells in this respect. Indeed, IAP inhibitors can also promote inflammation, which may improve or hamper their efficacy in killing cancer cells, an issue we now wish to explore and exploit.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapies to Enhance Immunity to Cancer
-
批准号:nhmrc : GNT1122311
-
项目类别:Early Career Fellowships
-
资助金额:$31.88万
-
财政年份:2017
-
负责人:Dr Conor Kearney
-
依托单位:
海外基金